Literature DB >> 6207136

Retinal oxygen tension and oxygen reactivity in retinopathy of prematurity in kittens.

J T Ernest, T K Goldstick.   

Abstract

In the first series of experiments, preretinal oxygen tensions were measured using microelectrodes in newborn kittens, at 6 +/- 2 days of age, following their placement in an atmosphere of 80 to 90% oxygen for 5 +/- 1 day. The oxygen exposure caused an obliteration of the normally developing retinal vasculature. Preretinal oxygen tensions in the resultant avascular retina were close to zero while those in the vascular retina were near normal. The avascular retina was a "sink" for ocular oxygen. Oxygen breathing resulted in expected increases in preretinal oxygen tension, but, surprisingly, the preretinal oxygen tension decreased with continued oxygen administration. Because the oxygen tension in the avascular retinal area is determined primarily by the choroidal circulation, we speculated that increased oxygen caused a decreased choroidal blood flow. In the second series of experiments, however, choroidal blood flow was measured in the kittens by applying a temperature probe to the sclera and oxygen breathing did not appear to have an effect. These results did not support the initial speculation. It may be that the decrease in preretinal oxygen tension observed with continued oxygen administration resulted from progressive increase in utilization.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207136

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.

Authors:  Steven J Budd; M Elizabeth Hartnett
Journal:  Arch Ophthalmol       Date:  2010-05

2.  Experimental studies on the pathogenesis of retinopathy of prematurity.

Authors:  M Prost
Journal:  Br J Ophthalmol       Date:  1988-05       Impact factor: 4.638

3.  Intraocular oxygen tension in eyes with proliferative diabetic retinopathy with and without vitreous.

Authors:  N Maeda; Y Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

4.  Ocular oxygen consumption during vitreoperfusion in the cat.

Authors:  N P Blair
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 5.  The pathogenesis of retinopathy of prematurity as it relates to surgical treatment.

Authors:  F L Kretzer; R S Mehta; E S Brown; H A Mintz-Hittner
Journal:  Doc Ophthalmol       Date:  1990-03       Impact factor: 2.379

6.  Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model.

Authors:  Yuta Saito; Abhineet Uppal; Grace Byfield; Steven Budd; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

7.  HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischaemia.

Authors:  Freya M Mowat; Ulrich F O Luhmann; Alexander J Smith; Clemens Lange; Yanai Duran; Sarah Harten; Deepa Shukla; Patrick H Maxwell; Robin R Ali; James W B Bainbridge
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

8.  Reduced severity of oxygen-induced retinopathy in the newborn rat after topical administration of timolol maleate. A preliminary study.

Authors:  B Ricci; G Calogero; A Caprilli; F M Quaranta-Leoni
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

Review 9.  The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model.

Authors:  M Elizabeth Hartnett
Journal:  Doc Ophthalmol       Date:  2009-07-29       Impact factor: 2.379

10.  Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity.

Authors:  Yuta Saito; Pete Geisen; Abhineet Uppal; M Elizabeth Hartnett
Journal:  Mol Vis       Date:  2007-06-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.